The overall goal of the proposed research is to improve the evaluation of vaccine efficacy and effectiveness in the field.
The specific aims of this application are to develop feasible designs and statistical procedures for Phase III HIV vaccine trials so as to estimate three different vaccine effects: vaccine efficacy for susceptibility to infection (VES); vaccine efficacy for reduction in infectiousness of infected vaccinated persons (VEI); and vaccine efficacy for reduction in illness progression in HIV infected persons (VEP). The researchers will also consider estimating the waning of such effects. Suggested trial designs will be based on the enrollment of uninfected primary participants who will be randomized to vaccine or placebo and followed prospectively. To estimate VEI, the researchers will augment the trials by recruiting sexual partners of primary participants prospectively or locating recent sexual partners of vaccine trial participants who have become infected, and then develop statistical methods for these study designs. To estimate VEP the researchers will compare surrogate marker information, such as plasma RNA or DNA levels or CD4 counts of infected vaccinated persons, to that for infected unvaccinated persons. The researchers will adapt the designs to the realities of the vaccine trials being planned in Thailand and Brazil. Finally, they will use simulations to generate data similar to those expected in different designs of HIV vaccine trials to test the statistical methods.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI040846-01A1
Application #
2005401
Study Section
AIDS and Related Research Study Section 2 (ARRB)
Project Start
1997-04-01
Project End
2000-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Emory University
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Hudgens, M G; Satten, G A; Longini Jr, I M (2001) Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncation. Biometrics 57:74-80
Longini Jr, I M; Hudgens, M G; Halloran, M E et al. (1999) A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. Stat Med 18:53-68
Datta, S; Halloran, M E; Longini Jr, I M (1999) Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household. Biometrics 55:792-8
Golm, G T; Halloran, M E; Longini Jr, I M (1999) Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials. Biometrics 55:94-101
Halloran, M E; Longini Jr, I M; Struchiner, C J (1999) Design and interpretation of vaccine field studies. Epidemiol Rev 21:73-88
Golm, G T; Halloran, M E; Longini Jr, I M (1998) Semi-parametric models for mismeasured exposure information in vaccine trials. Stat Med 17:2335-52